289 related articles for article (PubMed ID: 19545297)
1. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
Gebauer K; Shumack S; Cowen PS
Br J Dermatol; 2009 Oct; 161(4):897-903. PubMed ID: 19545297
[TBL] [Abstract][Full Text] [Related]
2. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N; Smith CC; Kaur M; Goldenberg G
J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
[TBL] [Abstract][Full Text] [Related]
3. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N; Smith CC; Kaur M; Goldenberg G
J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
[TBL] [Abstract][Full Text] [Related]
4. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.
Korman N; Moy R; Ling M; Matheson R; Smith S; McKane S; Lee JH
Arch Dermatol; 2005 Apr; 141(4):467-73. PubMed ID: 15837864
[TBL] [Abstract][Full Text] [Related]
5. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.
Hanke CW; Beer KR; Stockfleth E; Wu J; Rosen T; Levy S
J Am Acad Dermatol; 2010 Apr; 62(4):573-81. PubMed ID: 20133012
[TBL] [Abstract][Full Text] [Related]
6. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
Swanson N; Abramovits W; Berman B; Kulp J; Rigel DS; Levy S
J Am Acad Dermatol; 2010 Apr; 62(4):582-90. PubMed ID: 20133013
[TBL] [Abstract][Full Text] [Related]
7. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials.
Lebwohl M; Dinehart S; Whiting D; Lee PK; Tawfik N; Jorizzo J; Lee JH; Fox TL
J Am Acad Dermatol; 2004 May; 50(5):714-21. PubMed ID: 15097955
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms.
Harrison LI; Skinner SL; Marbury TC; Owens ML; Kurup S; McKane S; Greene RJ
Arch Dermatol Res; 2004 Jun; 296(1):6-11. PubMed ID: 15083310
[TBL] [Abstract][Full Text] [Related]
9. Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses.
Zeichner JA; Stern DW; Uliasz A; Itenberg S; Lebwohl M
J Am Acad Dermatol; 2009 Jan; 60(1):59-62. PubMed ID: 18937999
[TBL] [Abstract][Full Text] [Related]
10. Open-label study to assess the safety and efficacy of imiquimod 5% cream applied once daily three times per week in cycles for treatment of actinic keratoses on the head.
Rivers JK; Rosoph L; Provost N; Bissonnette R
J Cutan Med Surg; 2008; 12(3):97-101. PubMed ID: 18544290
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses.
Stockfleth E; Meyer T; Benninghoff B; Salasche S; Papadopoulos L; Ulrich C; Christophers E
Arch Dermatol; 2002 Nov; 138(11):1498-502. PubMed ID: 12437457
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
Alomar A; Stockfleth E; Dirschka T; Gupta G; Aractingi S; Dakovic R; Peris K
J Drugs Dermatol; 2016 Mar; 15(3):285-9. PubMed ID: 26954313
[TBL] [Abstract][Full Text] [Related]
13. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream.
Lee PK; Harwell WB; Loven KH; Phillips TJ; Whiting DA; Andres KL; Lee JH
Dermatol Surg; 2005 Jun; 31(6):659-64. PubMed ID: 15996416
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis.
Kose O; Koc E; Erbil AH; Caliskan E; Kurumlu Z
J Dermatolog Treat; 2008; 19(3):159-63. PubMed ID: 18569272
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial.
Brown VL; Atkins CL; Ghali L; Cerio R; Harwood CA; Proby CM
Arch Dermatol; 2005 Aug; 141(8):985-93. PubMed ID: 16103328
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses.
Jorizzo JL; Markowitz O; Lebwohl MG; Bourcier M; Kulp J; Meng TC; Levy S
J Drugs Dermatol; 2010 Sep; 9(9):1101-8. PubMed ID: 20865842
[TBL] [Abstract][Full Text] [Related]
17. Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream.
Hanke CW; Swanson N; Bruce S; Berman B; Kulp J; Levy S
J Drugs Dermatol; 2011 Feb; 10(2):165-70. PubMed ID: 21283921
[TBL] [Abstract][Full Text] [Related]
18. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head.
Alomar A; Bichel J; McRae S
Br J Dermatol; 2007 Jul; 157(1):133-41. PubMed ID: 17501955
[TBL] [Abstract][Full Text] [Related]
19. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream.
Shaffelburg M
J Drugs Dermatol; 2009 Jan; 8(1):35-9. PubMed ID: 19180894
[TBL] [Abstract][Full Text] [Related]
20. Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.
Gupta G; Stockfleth E; Peris K; Aractingi S; Alomar A; Dakovic R; Dirschka T
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1840-2. PubMed ID: 25174261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
